References
- Benezeder, T., Wolf, P. (2019). Resolution of plaque-type psoriasis: What is left behind (and reinitiates the disease). Springer Semin. Immunopathol, 32 (6), 1–12.10.1007/s00281-019-00766-z688141431673756
- Boehncke, W. H., Boehncke, S. (2014). More than skin-deep: The many dimensions of the psoriatic disease. Swiss Med. Wkly., 144 (171), 68–75.10.4414/smw.2014.1396824764145
- Boniface, K., Jacquemin, C., Darrigade, A. S., Dessarthe, B., Martins C., Boukhedouni, N. (2018). Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3. J. Invest. Dermatol., 138 (2), 355–364.10.1016/j.jid.2017.08.03828927891
- Cather, J. C., Crowley, J. J. (2014). Use of biologic agents in combination with other therapies for the treatment of psoriasis. Amer. J. Clin. Dermatol., 15 (6), 467–478.10.1007/s40257-014-0097-1423982525373522
- Chiricozzi, A., Romanelli,. P., Volpe, E., Borsellino, G., Romanelli, M. (2018). Scanning the immunopathogenesis of psoriasis. Int. J. Mol. Sci., 19 (1), 179–18510.3390/ijms19010179579612829316717
- Christophers, E. (2001) Psoriasis — epidemiology and clinical spectrum. Clin. Exp. Dermatol., 26 (4), 314–320.10.1046/j.1365-2230.2001.00832.x11422182
- Christophers, E., van de Kerkhof, P. C. (2019). Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol., 33 (4), 643–647.10.1111/jdv.1533930924245
- Cosentyx 150 mg powder for solution for injection. SmPC. https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf (accessed 15 March 2020).
- Danese, S., Vermeire, S., D’Haens, G., Panés J., Dignass, A., Magro F. (2020). DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial. J. Crohns Colitis, 14 (1), 49–52.10.1093/ecco-jcc/jjz203.052
- Dubertret, L., Mrowietz, U., Rank., A, Van De Kerkhof, P. C., Chimenti, S., Lotti, T. (2006). EUROPSO patient survey. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Brit. J. Dermatol., 155 (4), 729–736.
- Eder, L., Haddad, A., Rosen C. F., Lee K. A., Chandran V., Cook, R. (2016). The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study. Arthritis Rheum., 68 (4), 915–923.10.1002/art.3949426555117
- Enbrel 25 mg solution for injection in pre-filled syringe Enbrel 50 mg solution for injection in pre-filled syringe. SmPC. https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf on 10/03/2020 (accessed 01.03.2020).
- From evolution to revolution: IL-23 in the treatment of psoriasis patients. EMJ Dermatol., 6, 71–78. https://www.emjreviews.com/dermatology/symposium/from-evolution-to-revolution-il-23-in-the-treatment-of-psoriasis-patients (accessed 01.03.2020).
- Gaies, E., Jebabli, N., Trabelsi, S., Salouage, I., Charfi, R., Lakhal, M. (2012). Methotrexate side effects: Review article. J. Drug Metab. Toxicol., 3 (4), 1–5.10.4172/2157-7609.1000125
- Gisondi, P., Del Giglio, M., Girolomoni, G. (2017). Treatment approaches to moderate to severe psoriasis. Int. J. Mol., 18 (11), 2427–2429.10.3390/ijms18112427
- Global Psoriasis Atlas. https://globalpsoriasisatlas.org/statistics (accessed 20.04.2020).
- Gooderham, M. J., Papp, K. A., Lynd, C.W. (2018). Shifting the focus–the primary role of IL-23 in psoriasis and other inflammatory disorders. J. Eur. Acad. Dermatol. Venereol., 32 (7), 1111–1119.10.1111/jdv.14868
- Griffiths, C. E., Barker, J. N. (2007). Pathogenesis and clinical features of psoriasis. The Lancet, 370, 263–271.10.1016/S0140-6736(07)61128-3
- Hao, J. Q. (2014). Targeting interleukin-22 in psoriasis. Inflammation, 37 (1), 94–99.10.1007/s10753-013-9715-y23978911
- Hartmane, I., Mikažāns, I., Ivdra,. I, Dērveniece, A., Ančupāne, I. (2016). Experience of phototherapy in dermatological praxis in complex therapy of psoriasis patients. Proc. Latv. Acad. Sci. Section B, 70 (1), 7–12.10.1515/prolas-2016-0002
- Humira 40 mg solution for injection in pre-filled syringe Humira 40 mg solution for injection in pre-filled pen. SmPC. Last revised 08/09/2008. https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_en.pdf (accessed 15.03.2020).
- Ilumetri 100 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/09/2018. https://www.ema.europa.eu/en/documents/product-information/ilumetri-epar-product-information_en.pdf on 10/03/2020 (accessed 15.03.2020).
- Jain, S., Kaur, I. R., Das, S., Bhattacharya, S. N. Singh, A. (2009) T helper 1 to T helper 2 shift in cytokine expression: An autoregulatory process in superantigen-associated psoriasis progression? J. Med. Microbiol., 58 (2), 180–184.10.1099/jmm.0.003939-019141734
- Kerdel, F., Zaiac, M. (2015). An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Dermatol. Ther., 28 (6), 390–403.10.1111/dth.12267504207326258910
- Kyntheum 210 mg solution for injection in pre-filled syringe. SmPC. Last revised 17/07/2017. https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf (accessed 15.03. 2020).
- Li, K., Joshua, F. R., Marano, C., Zhang, H., Yang, F., Feagan, B. G. (2019). Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in Ulcerative Colitis. Z. Gastroenterol., 57 (5), 169–187.10.1055/s-0039-1691867
- Mahil, S. K., Capon, F., Barker J. N. (2016). Update on psoriasis immuno-pathogenesis and targeted immunotherapy. Springer Semin. Immunopathol., 38 (1), 11–27.
- Malik, B. T., Byrne, K. T., Vella, J. L., Zhang, P., Shabaneh, T. B., Steinberg, S. M. (2017). Resident memory T cells in skin mediate durable immunity to melanoma. Sci. Immunol., 2 (10), 35–47.10.1126/sciimmunol.aam6346552533528738020
- Marti, D. A.,Towne, J. E., Kricorian, G., Klekotka, P., Gudjonsson, J. E., Krueger, J. G. (2013). The emerging role of IL-17 in the pathogenesis of psoriasis: Preclinical and clinical findings. J. Invest Dermatol., 133 (1), 17–26.10.1038/jid.2012.194356899722673731
- Matos, T. R., O’Malley, J. T., Lowry, E. L., Hamm, D., Kirsch I. R. (2017). Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αā T cell clones. J. Clin. Invest., 127 (11), 4031–4041.10.1172/JCI93396566336628945199
- Mattozzi, C., Salvi M., D’epiro, S., Giancristoforo, S., Macaluso, L., Luci, C. (2013). Importance of regulatory T cells in the pathogenesis of psoriasis. Dermatology, 227 (2), 134–145.10.1159/00035339824051528
- Medicines to be reimbursed. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/en/cross-border-healthcare-contact-point/health-care-in-latvia/medicines-to-be-reimbursed on 06/04/2020 (accessed 15.04. 2020).
- Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B. (2011). Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J. Amer. Acad. Dermatol., 65 (1), 137–174.10.1016/j.jaad.2010.11.05521306785
- Ministry of Health of the Republic of Lithuania. http://sam.lrv.lt/en/ (accessed 15.04.2020).
- Möller, A. H, Erntoft, S., Vinding, G. R., Jemec G. B. (2015). A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values. Patient Relat. Outcome Meas., 6, 167–177.
- Monteleone, G., Pallone F., MacDonald, T. T., Chimenti, S., Costanz, A. (2011). Psoriasis: From pathogenesis to novel therapeutic approaches. Clin. Sci., 120 (1), 8–12.10.1042/CS2010016320846119
- Mrowietz, U., De Jong, E. M., Kragballe, K., Langley, R., Nast, A., Puig, L. (2014). A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol., 28 (4), 438–453.10.1111/jdv.1211823437792
- Mrowietz, U., Kragballe, K., Reich, K., Spul, P., Griffiths. C. E., Nast, A. (2011). Definition of treatment goals for moderate to severe psoriasis:A European consensus. Arch. Dermatol. Res., 303 (1), 1–10.
- Nast, A., Boehncke, W. H., Mrowietz, U., Ockenfels, H. M., Philipp, S., Reich, K. (2012). S3–Guidelines on the treatment of psoriasis vulgaris (English version). Update. J. Dtsch. Dermatol. Ges., 10, 1–95.10.1111/j.1610-0387.2012.07919.x22386073
- Order for the approval of the procedure for the treatment of psoriasis with medicinal products the purchase of which is covered by the compulsory health insurance fund’s budget. Ministry of Health of Republic of Lithuania. https://www.e-tar.lt/portal/en/legalAct/c51f3b408d8311e7a3c4a5eb10f04386/nHZdKhSspS on 06/04/2020 (accessed 15.04.2020) (in Lithuanian).
- Owczarczyk-Saczonek, A., Czerwińska, J., Placek, W. (2018). The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. Acta Dermatovenerol. Alp. Pannonica Adriat., 27 (1), 17–23.10.15570/actaapa.2018.4
- Parisi, R., Symmons, D. P, Griffiths, C. E, Ashcrof, D. M.(2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J. Investig. Dermatol.., 133 (2), 377–385.10.1038/jid.2012.33923014338
- Qu, N., Xu, M., Mizoguchi, I., Furusawa, J. I., Kaneko, K., Watanabe, K. (2013). Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases. Clin. Dev. Immunol., 34 (16), 231–235.10.1155/2013/968549372850723956763
- Rahman, P., Elder, J. T. (2005). Genetic epidemiology of psoriasis and psoriatic arthritis. Ann. Rheum. Dis., 64 (2), 37–49.10.1136/ard.2004.030775176686815708933
- Rahman, P., Siannis, F., Butt, C., Farewell, V., Peddle, L., Pellett, F (2006). TNFα polymorphisms and risk of psoriatic arthritis. Ann. Rheum. Dis., 65 (7), 919–923.
- Reich, K., Armstrong, A. W., Langley, R. G., Flavin, S., Randazzo, B., Li, S (2019). Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial. The Lancet, 394 (1 0201), 831–839.10.1016/S0140-6736(19)31773-8
- Reich, K. (2012). The concept of psoriasis as a systemic inflammation: Implications for disease management. J. Eur. Acad. Dermatol. Venereol., 26, 3–11.10.1111/j.1468-3083.2011.04410.x22356630
- Reich, K., Burden, A. D., Eaton, J. N., Hawkins, N. S. (2012). Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials. Brit. J. Dermatol., 166 (1), 179–188.10.1111/j.1365-2133.2011.10583.x21910698
- Reich, K., Nestle, F. O., Papp, K., Ortonne, J. P., Evans, R, Guzzo, C., Li, S., Dooley, L. T., Griffiths, C. E., (2005). EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. The Lancet, 366 (9494), 1367–1374.
- Reimbursemen drug list. Nacionālais Veselības Dienests [National Health Service]. http://www.vmnvd.gov.lv/lv/kompensejamie-medikamenti/kompensejamo-zalu-saraksts from 06/04/2020 (accessed 15.04. 2020).10.36268/JTER/15202
- Remsima 100 mg powder for concentrate for solution for infusion. SmPC. Last revised 21/06/2018. https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf (accessed 15.04. 2020).
- Rendon, A, Schäkel, K. (2019). Psoriasis pathogenesis and treatment. Int. J. Mol. Sci., 20 (6), 1475.10.3390/ijms20061475647162830909615
- Signorovitch, J. E., Betts, K.A., Yan, Y. S., LeReun, C., Sundaram, M., Wu, E. Q., Mulani, P. (2015). Comparative efficacy of biological treatments for moderate-to-severe psoriasis: A network meta-analysis adjusting for cross-trial differences in reference arm response. Brit. J. Dermatol., 172 (2), 504–512.10.1111/bjd.1343725288183
- Skyrizi 75 mg solution for injection in pre-filled syringe. SmPC. Last revised 26/04/2019. https://www.ema.europa.eu/en/documents/product-information/skyrizi-epar-product-information_en.pdf (accessed 15.04.2020).
- STELARA 45 mg solution for injection STELARA 90 mg solution for injection STELARA 45 mg solution for injection in pre-filled syringe STELARA 90 mg solution for injection in pre-filled syringe. SmPC. Last revised 19/09/2013. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf (accessed 15.04.2020).
- Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie A., Van Voorhees A. S. (2017). Psoriasis and comorbid diseases: Epidemiology. J. Amer. Acad. Dermatol.. 76 (3), 377–390.10.1016/j.jaad.2016.07.064573165028212759
- Taltz 80 mg solution for injection in pre-filled syringe. SmPC. Last revised 25/04/2016. https://www.ema.europa.eu/en/documents/product-information/taltz-epar-product-information_en.pdf (accessed 15.04. 2020).
- Tervishoiuteenuste loetelu. https://www.haigekassa.ee/partnerile/raviasutusele/tervishoiuteenuste-loetelu on 06/04/2020 (accessed 15.04.2020).10.1055/s-0040-1721630
- Tremfya 100 mg solution for injection in pre-filled syringe. Tremfya 100 mg solution for injection in pre-filled pen. SmPC. Last revised 10/11/2017. https://www.ema.europa.eu/en/documents/product-information/tremfya-epar-product-information_en.pdf (accessed 15.04. 2020).
- Use of public budget resources to pay national reimburses [Valsts budžeta līdzekļu izlietojums valsts kompensējamo zāļu apmaksā]. Nacionālais Veselības Dienests [National Health Service]. http://vmnvd.gov.lv/lv/ligumpartneriem/operativa-budzeta-informacija/valsts-budzeta-lidzeklu-izlietojums-valsts-kompensejamo-zalu-apmaksa on 07/04/2020 (accessed 15.04.2020).
- Vide, J., Magina S, (2017). Moderate to severe psoriasis treatment challenges through the era of biological drugs. An. Bras. Dermatol., 92 (5), 668–674.10.1590/abd1806-4841.20175603567470029166504
- Wada, Y., Cardinale, I., Khatcherian, A., Chu, J., Kantor, A. B., Gottlieb, A.B. (2012). Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis. PloS One, 7 (4), 1371–1380.10.1371/journal.pone.0035069332087322493730
- Watanabe, R. (2019). Protective and pathogenic roles of resident memory T cells in human skin disorders. J. Dermatol. Sci., 31 (5), 151–157.10.1016/j.jdermsci.2019.06.00131272851
- Yeung, H., Takeshita, J., Mehta, N. N., Kimmel, S. E., Ogdie, A., Margolis, D. J., Shin, D. B., Attor, R., Troxel, A. B., Gelfand, J. M. (2013). Psoriasis severity and the prevalence of major medical comorbidity: A population-based study. JAMA Dermatol., 149 (10), 1173–1179.10.1001/jamadermatol.2013.5015380048723925466